The tyrosine kinase inhibitor dasatinib exerts immunosuppressive effects on T-cells and NK-cells in vitro. However, in some dasatinib-treated leukemia patients, clonal lymphocytosis with large granular lymphocyte (LGL) morphology develops, and this is associated with enhanced therapeutic responses. To elucidate the mechanistic basis for this paradoxical observation, we conducted detailed phenotypic and functional analyses of T-cell and NK-cell populations from 25 dasatinib-treated leukemia patients. All tested patients with LGL expansions (15/16) were cytomegalovirus (CMV) immunoglobulin (IgG) seropositive with high frequencies of CMV-specific CD8 þ T-cells; 5/16 LGL patients also experienced symptomatic CMV reactivation during dasatinib therapy. Expanded T-cell and NK-cell populations exhibited late differentiated (CD27 À CD57 þ ) phenotypes; this was associated with a predisposition to apoptosis within the T-cell compartment and impaired NK-cell cytotoxicity. Only 3/9 non-LGL patients were CMV IgG seropositive. Dasatinib inhibited in vitro lymphocyte functions, similarly in LGL patients and controls. Notably, distinct CD8 high and CD8 low T-cell subsets were observed in LGL patients; this phenotypic dichotomy was also apparent in CMV-specific CD8 þ T-cell populations, and exhibited features consistent with antigen-driven activation. In addition, plasma levels of IP-10, IL-6, monokine induced by interferon-c and interleukin-2R were significantly increased in LGL patients. These data provide evidence that dasatinib-associated LGL expansion is linked to CMV reactivation and suggest a potential mechanism for this phenomenon.
Introduction
Chronic myeloid leukemia (CML) epitomizes the concept of a hematological malignancy caused by dysregulated signal transduction. More than 90% of all CML patients have the translocation t (9;22) , which leads to the formation of a BCR-ABL fusion protein with continuous tyrosine kinase activity that is responsible for the malignant phenotype. Specific tyrosine kinase inhibitor therapy with imatinib (Glivec/Gleevec, Novartis, Basel, Switzerland) is the gold standard for the treatment of CML. 1 However, as imatinib resistance or intolerance may occur, second-line tyrosine kinase inhibitors have entered the clinic; examples include nilotinib (Tasigna, Novartis), 2 which is highly selective, and dasatinib (Sprycel, Bristol-Myers Squibb, New York, NY, USA). 3 In addition to BCR-ABL, dasatinib also targets SRC and TEC kinases that are known to be key factors in the regulation of immune responses. 4, 5 The broader target profile of dasatinib not only implies its less susceptibility to the development of resistance, but also the potential for more potent modulation of immune cell subsets. Indeed, immunosuppressive effects on T-cells and NK-cells have been described in vitro for dasatinib [6] [7] [8] [9] and other tyrosine kinase inhibitors. [10] [11] [12] This is in line with observations in single center clinical case series. 13 However, in large phase II/III clinical trials, increased infection rates due to immunosuppression have not been observed. 14 Recently, in a subset of CML or Philadelphia chromosome positive (Ph þ ) acute lymphocytic leukemia (ALL) patients receiving dasatinib, the development of a chronic, oscillating lymphocytosis has been observed in vivo. This dasatinibinduced lymphocytosis typically comprises monoclonal or oligoclonal CD8 þ T-cell or NK-cell large granular lymphocyte (LGL) expansions and is associated with enhanced, long-lasting therapeutic responses in patients with advanced leukemia. 15, 16 The CD8 þ T-cell or NK-cell clones are present during the diagnostic phase of the disease and expand with dasatinib therapy, leading to a numerical and fractional lymphocytosis. 17 Thus, dasatinib does not induce these clones, but rather appears to promote their preferential expansion.
To elucidate the mechanisms underlying dasatinib-associated LGL expansions in more detail, we analyzed T-cell and NK-cell effector functions (activation, proliferation, degranulation, cytotoxicity and the secretion of soluble factors) directly ex vivo. Dasatinib was used in vitro at clinically relevant doses of 10 and 50 nM, thereby mimicking peak and steady state concentrations. 7, 18 In addition, polychromatic flow cytometric analyses were conducted to determine the phenotypic characteristics of T-cell subsets and NK-cells in patients on continuous dasatinib treatment with and without LGL expansions. Plasma samples were assayed for soluble immune mediators in parallel, and cytomegalovirus (CMV) load measurements were conducted as indicated on clinical grounds.
Materials and methods

Reagents
Dasatinib was synthesized according to the published procedure, 19 dissolved in dimethyl sulfoxide (DMSO) and purity-tested as described previously. 7, 10 All functional assays were conducted in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (R10 medium). DMSO as a solvent control for dasatinib was included in all functional assays performed ex vivo. Interleukin-2 (IL-2; Proleukin, Chiron, Emeryville, CA, USA) was applied when indicated at 2000 IU/ml.
Patient samples
Frozen peripheral blood mononuclear cells (PBMCs), bone marrow mononuclear cells (BMMCs), and plasma from CML or Ph þ ALL patients on dasatinib therapy were analyzed, together with PBMC and plasma samples from healthy controls ( Table 1) . 15, 17 Measurements of plasma CMV DNA viral load were performed on the basis of clinical indications using a quantitative polymerase chain reaction assay, with a detection limit of 250 copies/ml plasma. Dasatinib patients were grouped according to the presence or absence of LGL expansions, defined as an increased absolute lymphocyte count 43.6 Â 10 9 /l with morphological characteristics of LGLs. Written informed consent was obtained from all patients and healthy controls. The study was conducted in accordance with the principles of the Helsinki declaration and was approved by the Helsinki University Central Hospital Ethics Committee.
Cytokine and chemokine determination
Plasma from patients with CML or Ph þ ALL treated with dasatinib (n ¼ 23), and healthy controls (n ¼ 10) was analyzed for the following soluble factors using a Human Cytokine 25-plex Panel (Invitrogen by Life Technologies, Carlsbad, CA,  USA) according to the manufacturer's instructions: IL-1b,  IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12,  IL-13, IL-15, IL-17, tumor necrosis factor-a, interferon (IFN)-a,  granulocyte macrophage-colony stimulating factor, macrophage  inflammatory protein-1a (CCL3), macrophage inflammatory  protein-1b (CCL4), IFN-g-inducible protein-10 (IP-10/CXCL10) , monokine induced by IFN-g (MIG/CXCL9), eotaxin (CCL11), RANTES (CCL5), monocyte chemoattractant protein-1/CCL2 and IFN-g. Measurement and analysis were performed using the Bio-Plex 200 System (BioRad, Hercules, CA, USA).
Peptide/HLA-A*0201 tetrameric complexes Fluorochrome-labeled tetrameric peptide/HLA-A*0201 (pHLA-A*0201) complexes were produced and used as described previously. 20 ExtrAvidin-R-PE (Sigma-Aldrich, St Louis, MO, USA), streptavidin-APC (Prozyme, Hayward, CA, USA) or streptavidin-QDot 705 (Molecular Probes/Invitrogen by Life Technologies) were used for tetramerization.
Flow cytometry
Live/dead fixable Aqua or Violet dyes (Molecular Probes/ Invitrogen) were used to exclude dead cells from the analysis; aCD14 and aCD19 monoclonal antibodies (Caltag/Invitrogen), both conjugated to Pacific Blue, were used to exclude monocytes and B-cells, respectively. The following monoclonal antibodies were used for polychromatic phenotypic analyses: aCD3-H7APC (BD Biosciences, Franklin Lakes, NJ, USA); aCD4-Cy5.5PE (Caltag/Invitrogen by Life Technologies); aCD8-Cy7PE and aCD57-FITC (BD Pharmingen, Franklin Lakes, Table 1 Characteristics of study patients with and without LGL expansions during treatment with dasatinib for CML or ALL Clonality of lymphocytes was confirmed by analyzing T-cell receptor (TCR) g-and d-gene rearrangements by PCR as described earlier. 17 Of note, clonal TCR rearrangments were found in both, LGL and non-LGL CML patients. 17 Positive products (confirmed by sequencing) are marked in the table. c Therapy ongoing.
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A Kreutzman et al NJ, USA); aCD8-QDot 705 (Molecular Probes/Invitrogen); aCD27-Cy5PE, aCD45RO-ECD, aCD69-APC and aCD127-PE (Beckman Coulter, Brea, CA, USA) and biotinylated aPD-1 (R&D Systems, Abingdon, UK). For visualization of PD-1 þ events, a secondary staining was performed with streptavidin-Pacific Blue (Invitrogen). In some experiments, Annexin V-FITC (BD Pharmingen) was used for the identification of apoptotic cells directly ex vivo; in other experiments, aCD16-PE (BD, Franklin Lakes, NJ, USA) and aCD56-APC (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) were used. Stained samples for polychromatic analyses were acquired and recorded using a customized FACSAria II flow cytometer (BD Biosciences) equipped for the simultaneous detection of 18 fluorescent parameters; data were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). For experiments limited to a maximum of four fluorescent parameters, samples were acquired and recorded using a FACSCalibur flow cytometer (BD Biosciences); data were analyzed using CellQuest software (BD). All cell sorts were conducted to a purity of 498% using the customized FACSAria II flow cytometer.
Apoptosis assay
PBMCs (1 Â 10 6 cells/ml) were either unstimulated or stimulated with 5 mg/ml OKT3 (Orthoclone, Janssen-Cilag, North Ryde, NSW, Australia) and antibodies against the costimulatory molecules CD28 and CD49d (1 mg/ml each; BD Pharmingen) for 4 days after overnight rest in R10 medium, cells were then harvested and stained with Annexin V-PE (BD Pharmingen) and 7-amino-actinomycin D (7AAD; Sigma-Aldrich). Apoptotic cells were defined by flow cytometry as 7AAD -/Annexin V þ ; late apoptotic/necrotic cells were defined as 7AAD þ /Annexin V þ .
NK-cell expansion
Polyclonal NK-cells were generated as described previously.
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In brief, non-adherent peripheral blood lymphocytes obtained from healthy controls after plastic adherence were cocultured with the irradiated EBV-transformed B cell line RPMI 8866, a kind gift from Dr Jö rg Wischhusen, at a ratio of 4:1 for 8-11 days in R10 medium. NK-cells were defined as CD3 À , CD16 þ and/or CD56 þ ; purity was determined by flow cytometry using aCD3-PerCP (Biolegend, San Diego, CA, USA) and aCD16/56-APC (both from Miltenyi). Experiments were performed when the purity of expanded NK-cells exceeded 75%.
Transfection of target cells
K562 cells, a kind gift from Dr Ulrike Kämmerer, were transfected at 300 V with the firefly luciferase (fLuc):zeocin (zeo) mammalian expression vector consisting of an engineered fusion between the fLuc and zeo resistance genes under the control of the CMV IE promoter (InvivoGen, San Diego, CA, USA) cloned into the pcDNA3.1( þ ) plasmid backbone as described previously. 22 The vector was a kind gift from Dr Jörg Wischhusen. K562 fLuc þ cells were cultivated in zeocin-containing R10 medium. 
NK-cell cytotoxicity assay
NK-cell cytokine production and degranulation assay
PBMCs were pretreated either with DMSO or with 10 or 50 nM dasatinib for 1 h. The monoclonal antibodies aCD107a-FITC and aCD107b-FITC (both BD Pharmingen) were then added and NKcells (CD3 À , CD16 þ and/or CD56 þ ) were stimulated with untreated and untransfected K562 cells in the presence of brefeldin A and GolgiStop (BD Biosciences). After 6 h, the cells were surface-stained with aCD3-PerCP (Biolegend) and aCD16/56-APC (both from Miltenyi), then fixed/permeabilized using Cytofix/ Cytoperm (BD Biosciences), and stained intracellularly with aTNF-a-PE and aIFN-g-PE (BD Pharmingen). Data were acquired using a 4-color FACSCalibur flow cytometer (BD Biosciences) and analyzed with CellQuest software (BD Biosciences).
Carboxyfluorescein diacetate succinimidyl ester proliferation assay
PBMCs were suspended in phosphate-buffered saline (1 Â 10 6 cells/ml) and labeled with the vital dye carboxyfluorescein diacetate succinimidyl ester (Molecular Probes) at a final concentration of 0.25 mM as described previously.
7,10 After overnight rest, carboxyfluorescein diacetate succinimidyl esterlabeled cells were pre-incubated with dasatinib or DMSO as indicated for 1 h, then cultured for 4 days in the presence of 5 mg/ml OKT3 and aCD28/aCD49d (1 mg/ml each).
CMV-specific CD8
þ T-cell proliferation, cytokine production and degranulation assays
PBMCs from HLA-A*02 þ and CMV immunoglobulin (IgG) seropositive LGL patients, a non-LGL patient and healthy donors were labeled with carboxyfluorescein diacetate succinimidyl ester, and stimulated with the CMV pp65 495À503 peptide NLVPMVATV, which is restricted by HLA-A*02, at a concentration of 2 mM for 6 days in the presence of aCD28/aCD49d (1 mg/ ml each). The cells were then harvested, stained with the CMV pp65 495À503 /HLA-A*0201-APC tetramer and aCD8-PerCP (BD Biosciences), and analyzed by flow cytometry as described previously. 7, 10 Expression of the degranulation markers CD107a/b, together with intracellular cytokine production, in the presence or absence of dasatinib, was evaluated in 5-h assays as described above for NK-cells.
T-cell receptor (TCR) clonotyping
Clonotypic analysis of cognate antigen-specific CD8 þ T-cell populations was conducted, as described previously, with minor modifications. 23 Briefly, 2232-5000 tetramer-labeled CD3 þ CD8 þ T-cells were sorted viably into 1.5-ml microtubes (Sarstedt AG & Co., Nü mbrecht, Germany) containing 100 ml RNAlater (Applied Biosystems by Life Technologies, Carlsbad, CA, USA), and unbiased amplification of all expressed TRB gene products was conducted using a template-switch anchored reverse transcription-PCR with a 3 0 -TRB constant region primer (5 0 -TGGCTCAAACAAGGAGACCT-3 0 ). Amplicons were subcloned, sampled, sequenced and analyzed as described previously. 20 The IMGT nomenclature is used in this report. 24 
Statistical analyses
GraphPad Prism software (GraphPad, La Jolla, CA, USA) was used for statistical analysis of data. Results are expressed as mean±s.e.m. unless indicated otherwise. Statistical significance was determined using the non-parametric Kruskal-Wallis test, the paired two-tailed Student's t-test or one way analysis of variance, and defined as Po0.05.
Results
Association of LGL expansions with CMV seropositivity, CMV reactivation and elevated plasma levels of IP-10, IL-6, MIG and IL-2R
In all, 15/16 patients in our cohort with LGL expansions were CMV IgG seropositive (IgG serostatus only unknown for patient 9), whereas only 3/9 non-LGL patients were CMV IgG seropositive. Most patients with LGL expansions also exhibited high frequencies of CMV-specific CD8 þ T-cells (range, 0.7-15.6% of the total CD3 þ T-cell pool) as determined by staining with pHLA-A*0201 tetrameric complexes bearing the immunodominant pp65-derived (residues 495-503) epitope NLVPMVATV ( Table 2 ). Of note, 5/16 LGL patients and 0/9 non-LGL patients experienced symptomatic (persistent lowgrade fever) CMV reactivations (Table 1) , which were confirmed by PCR. However, it should be noted that CMV load measurements were not performed in asymptomatic patients. There was no evidence for reactivation of other herpes viruses. In addition, significantly elevated levels of IP-10 (CXCL10), IL-6, MIG (CXCL9) and IL-2R were present in the plasma of patients with LGL expansions compared with healthy controls (Figure 1) . Table 2 Phenotypic features of CD8 + and CD4 + T-cell populations (Table 1) are identified with unfilled symbols. Comparisons between groups were performed using the non-parametric KruskallWallis test. Statistically significant differences were observed between healthy controls and LGL patients for IP-10 (P ¼ 0.0011), IL-6 (P ¼ 0.0077), MIG (P ¼ 0.0090) and IL-2R (P ¼ 0.0186) levels; these differences held irrespective of the sampling time point (data not shown). In the IL-6 graph, one data point in the LGLÀ group was out of range (3576.5 pg/ml) and is not shown.
Figure 2 Effects of dasatinib on activation and proliferation of CMV-specific CD8
þ T-cells from LGL patients and healthy controls in response to cognate viral antigen directly ex vivo. (a) PBMCs were labeled with carboxyfluorescein diacetate succinimidyl ester, then stimulated with the CMV pp65 495À503 peptide NLVPMVATV (NLV) at a concentration of 2 mM for 6 days in the presence of aCD28/aCD49d at 1 mg/ml each (CS: costimulation). Antigen-specific proliferation in the absence and presence of dasatinib at 10 or 50 nM was evaluated for CD8
þ T-cells that stained with the CMV pp65 495À503 /HLA-A*0201 tetramer. Data are shown as the mean ± s.e.m for LGL patients (n ¼ 4, grey), healthy controls (n ¼ 2, white) and a non-LGL patient (n ¼ 1, black). 
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Notably, the highest plasma levels of these soluble factors were detected in the patients who experienced symptomatic CMV reactivations during dasatinib therapy (Figure 1 ). These data are consistent with previous studies, which have demonstrated increased levels of IFN-g stimulated gene products, such as IP-10 and MIG, in the plasma of patients with LGL expansions unrelated to dasatinib treatment. 25 There were no significant differences between groups for any of the other 21 soluble CMV and dasatinib-associated LGLfactors measured in plasma. Thus, the cytokine perturbations in patients with dasatinib-associated LGL expansions are restricted and may reflect virus-specific responses dominated by IFN-g rather than general immune activation.
Increased apoptotic susceptibility of T-cells from patients with LGL expansions
In vitro, CD3
þ T-cells from LGL patients (n ¼ 8) demonstrated significantly higher rates of apoptosis compared with non-LGL patients (n ¼ 6) or healthy controls (n ¼ 4) after 4 days without stimulation (Po0.05 for both comparisons); no significant differences for NK-cells were observed between the three groups (data not shown). The CD3 þ T-cells from LGL patients were also more sensitive to activation-induced cell death after stimulation with the murine monoclonal antibody OKT3, which cross-links the CD3 component of the CD3/TCR complex, leading to significantly higher rates of apoptosis compared with healthy controls (Po0.05) and a trend towards higher rates of apoptosis compared with non-LGL patients. In contrast, no differences were observed in either untreated or OKT3-stimulated T-cells with regard to the fraction of late apoptotic/necrotic cells (7AAD þ /annexin V þ ; data not shown). Thus, with the caveat that in vitro conditions do not necessarily recapitulate the complexity of cellular signaling networks in vivo, it appears that enhanced survival does not explain the T-cell expansions observed in dasatinib-associated LGL lymphocytosis; instead, these data point towards a proliferative basis for the observed T-cell expansions. Thus, we proceeded to examine the effects of dasatinib on T-cell and NK-cell activation, proliferation and function directly ex vivo.
Ex vivo modulation of T-cell activation, proliferation, degranulation and cytokine production by dasatinib Initially, we examined the effects of dasatinib on CD3 þ , CD4 þ and CD8 þ T-cell subsets stimulated non-specifically with OKT3 ex vivo. Consistent with previous studies, we observed significant dose-dependent inhibitory effects on T-cell activation, proliferation, degranulation and cytokine production in all subsets (Supplementary Figure S1) . Importantly, no differences in dasatinib sensitivity were observed with respect to any of these effects between LGL patients, non-LGL patients and healthy controls (data not shown). Notably, during these experiments, we also observed a dichotomy within the CD8 þ T-cell compartment of LGL patients. Specifically, two distinct CD8 þ T-cell subpopulations, CD8 high and CD8 low , could be discerned based on differential CD8 expression levels (Supplementary Figure S1C,D) . The CD8 high subset exhibited substantially greater degranulation and cytokine production in response to OKT3 stimulation compared with the CD8 low and CD4 þ subsets (Supplementary Figure S1C-E) . Moreover, distinct CD8 high and CD8 low T-cell subsets were not observed in healthy controls or non-LGL patients, with the exception of one non-LGL patient in whom LGL expansions may still develop.
As CD8 þ T-cell-mediated immunity is essential for the longterm control of persistent DNA viruses, and 5/16 LGL patients experienced symptomatic CMV reactivation (Table 1) , we further evaluated CD8 þ T-cell proliferation in response to the CMV pp65 495À503 peptide antigen (NLVPMVATV) over a period of 6 days. CMV-specific CD8 þ T-cell proliferation was suppressed in vitro in the presence of 50 nM dasatinib (Po0.001); however, in contrast to bulk CD8 þ T-cell populations (Supplementary Figure S1B) , no inhibition was observed with 10 nM dasatinib (Figure 2a ). No differences were observed when LGL patients (n ¼ 4) were compared with either healthy controls (n ¼ 2) or a non-LGL patient (patient 19, Table 1 ). Of note, the majority of non-LGL patients in our cohort were either HLA-A*02 À or CMV IgG seronegative; thus, only extremely limited CMV-specific functional studies were possible in this group (Figures 2a and d) .
Strikingly, we also observed distinct CD8 high and CD8 low subsets within the NLVPMVATV-specific CD8 þ T-cell populations in patients with LGL expansions (n ¼ 8). In healthy controls (n ¼ 3) and one non-LGL patient (patient 19; Table 1 ), only NLVPMVATV-specific CD8 high subpopulations were detected; the distinct CD8 low subpopulation was confined to LGL patients (Figures 3a and b) . When NLVPMVATV-specific CD8 þ T-cells were stimulated with cognate peptide, both the CD8 high and CD8 low subsets exhibited degranulation and cytokine production; these functions were inhibited by dasatinib in a dose-dependent manner, with minimal and almost complete suppression at concentrations of 10 and 50 nM, respectively (Figures 2b-d) . Of note, in LGL patients, both degranulation and cytokine production were significantly more pronounced in the CD8 high subset (n ¼ 8; Figure 2c ). Furthermore, dasatinib effectively abrogated downregulation of both TCR and CD8 in the CD8 high subpopulation in vitro, which could be a contributing factor in the generation and maintenance of persistent LGL expansions (data not shown). 26 Importantly, the dominant TCR clonotypes and phenotypic features of the CD8 high and CD8 low NLVPMVATVspecific subsets were similar (Figure 3 ), thereby indicating that these cells were derived from the same precursors and that the observed CD8 downregulation likely reflected a state of recent activation. One minor deviation from this general observation occurred in patient 13, in whom the NLVPMVATV-specific CD8 low population appeared more differentiated (CD45RO dim CD57 þ ) and expressed greater levels of programmed death-1 (PD-1); this is consistent with antigen-driven effects in the context of combined T-cell and NK-cell LGL expansions.
Ex vivo modulation of expanded NK-cell cytotoxic activity, degranulation and cytokine production by dasatinib A modified biophotonic luciferase assay was used to measure NK-cell cytotoxic activity against transiently transfected K562 cells. Expanded NK-cells from LGL patients showed significantly impaired cytotoxic activity against K562 cells compared with NK-cells from non-LGL patients or healthy controls (Po0.05 for both comparisons; Supplementary Figure S2A ). Of note, insufficient numbers of NK-cells were available from LGL patients with CD8
þ T-cell expansions to conduct this assay. The impaired in vitro cytotoxic activity of NK-cells from LGL patients may be due to exhaustion based on excessive in vivo proliferation or a state of reversible anergy. In line with this hypothesis, NK-cell cytotoxic activity was restored to a substantial extent after pretreatment with IL-2 for 18 h (Supplementary Figure S2B ). The cytotoxic activity of NK-cells, either with or without IL-2 pretreatment, was inhibited by dasatinib in all three groups irrespective of differences in activity (Supplementary Figure S2C,D) . In contrast, when PBMCs were stimulated with untransfected K562 cells without IL-2 pretreatment, no differences in NK-cell degranulation and cytokine production were observed for NK LGL patients (n ¼ 5; Supplementary Figure S2E ,F) compared with non-LGL patients (n ¼ 3) or healthy controls (n ¼ 3). Dasatinib led to a significant reduction in CD107a/b expression and cytokine production in NK LGL patients and healthy controls at a concentration of 10 nM (Po0.01 for all comparisons); however, significant inhibition was not achieved at this concentration in non-LGL patients, which may reflect the small sample size (n ¼ 3). Degranulation and cytokine production were completely inhibited by dasatinib at a concentration of 50 nM in all three groups. The contrasting cytotoxicity and degranulation data could reflect differential assay conditions or differences in the cytotoxic arsenal available for deployment.
Detailed phenotypic characterization of T-cells and NK-cells in subjects with or without LGL expansions
Analyzed directly ex vivo, patients with dasatinib-associated T LGL expansions had higher frequencies of CD8 þ T-cells and lower frequencies of CD4 þ T-cells compared with non-LGL patients or patients with NK LGL or T þ NK LGL expansions (Table 2) . Although the frequencies of PD-1 þ CD57 À cells in the CD8 þ T-cell compartment were highest in non-LGL patients, subjects with LGL tended to have higher frequencies of PD-1 þ cells that also expressed CD57. Annexin V was only expressed by very few cells in patients with or without LGL expansions, and there were no differences between groups (data not shown). The majority of CD8 þ and CD4 þ T-cells from patients with T or T þ NK LGL expansions were CD45RO þ CD27 À and many of these cells, especially in the CD8 þ T-cell compartment, co-expressed CD57 (with lower percentages in CD4 þ T-cells; Table 2 ). As described above, high frequencies of CMV-specific CD8 þ T-cells were observed in patients with LGL expansions; these cells also exhibited a predominant CD45RO þ CD27
À phenotype and many co-expressed CD57 ( Table 2 ). The latter could not be assessed in non-LGL patients, as they were mostly either HLA-A*02 À or CMV IgG seronegative. Collectively, these phenotypic features indicate that these cells are primed, late differentiated effector memory T-cells. 27 The majority of NKcells exhibited a CD45RO À CD27 À CD57 þ phenotype, especially in patients with NK or T þ NK LGL expansions (Table 3) . This phenotype is typical for terminally differentiated effector memory cells that are characterized by replicative senescence and are found at higher frequencies in chronic viral infections. 28, 29 Of note, three LGL patients (patients 1, 3 and 7; Table 1 ) had CD8 þ T-cell populations specific for the PR1 leukemia-associated peptide derived from proteinase 3 (1.1, 0.6 and 0.05% of the total CD8 þ T-cell population, respectively); of these, 490% were CD45RO þ CD27 À and the majority (71-100%) were also CD57 þ . All of these patients had advanced disease (ALL and CML in blast crisis) that had relapsed after allogeneic bone marrow transplantation and, in two patients (patients 1 and 7; Table 1 ) the disease had subsequently quiesced into prolonged remission (42 years) with dasatinib monotherapy, suggesting an unexpectedly good response to treatment. In other patients studied, no PR1-specific CD8 þ T-cells were observed. Overall, these analyses demonstrate that T-cells and NK-cells in dasatinib-associated T, NK and T þ NK LGL expansions characteristically display a late or terminally
Longitudinal phenotypic characterization of T-cell subsets in a patient with combined T and NK LGL expansion
To increase our understanding of the LGL phenomenon, we conducted a longitudinal examination of T-cell subsets in one patient (patient 6, CML in blast crisis; Table 1 ) with T þ NK LGL expansion (TCRd rearrangement in NK-cells and TCRg rearrangement in CD8 þ T-cells). 17 Dramatic expansions of both total and NLVPMVATV-specific CD8 þ T-cells were observed; the latter comprised up to 14.2% of the total CD3 þ T-cell population in PBMCs and up to 15.1% in BMMCs (Figure 4a) . The clonal T þ NK LGL expansions emerged 12 weeks after dasatinib was first administered (time point 2; Figure 4 ). This paralleled the expansion of NLVPMVATV-specific CD8 
T-cells. A high fraction of CD8
þ T-cells expressed CD45RO, but not CD27 ( Figure 4b) ; furthermore, a very high fraction of CD8 þ T-cells expressed CD57, but relatively few expressed or coexpressed PD-1 (Figure 4c ). The latter was also true for CD4
þ Tcells (Figure 4h) . Only a minority of total CD8
þ T-cells and NLVPMVATV-specific CD8 þ T-cells exhibited an activated phenotype (CD69 þ ), but more activated cells were present at the first time point (Figures 4d and g) . Similarly, the majority of total CD8
þ T-cells and NLVPMVATV-specific CD8 þ T-cells were CD127
À during the period of study, although higher expression of this homeostatic memory marker was apparent at the first time point (Figures 4d and g ). Most NLVPMVATVspecific CD8 þ T-cells (both CD8 high and CD8 low ) expressed CD45RO, but not CD27 ( Figure 4e) ; a high fraction also expressed CD57 (Figure 4f ). However, in contrast to the total CD8 þ T-cell population, a high fraction of NLVPMVATVspecific CD8 þ T-cells expressed both PD-1 and CD57; this PD-1 þ CD57 þ fraction was less prominent at time points characterized by higher CMV loads, whereas the PD-1 þ CD57
À fraction displayed the opposite pattern (Figure 4f ). Overall, these data are consistent with the contrasting effects of an antigendriven activation and differentiation process attenuated by the inhibitory effects of dasatinib.
Discussion
The dose-dependent immunosuppressive effects of dasatinib observed in vitro are at odds with apparent immunostimulatory effects observed in vivo. These differences may be explained, at least in part, by the short half-life of dasatinib in vivo, which leads to intermittent kinase-mediated target inhibition. 30 Previously, we showed that CD4 þ regulatory T-cell numbers were significantly lower in CML patients compared with healthy controls; this distinction was especially marked in LGL patients, who exhibited substantially lower regulatory T-cell numbers compared with non-LGL patients (data not shown). 15, 31 However, the observation herein that LGL expansions in dasatinib-treated patients are associated with CMV reactivation provides additional insight into these seemingly contradictory observations.
In this study, we observed high frequencies of CD8 þ T-cells specific for the CMV pp65 495À503 peptide antigen (NLVPMVATV) in LGL patients; furthermore, a high proportion of LGL patients (31%) experienced symptomatic CMV reactivation during dasatinib therapy, while there was no evidence for reactivation of other herpes viruses. It is feasible that CMV reactivation was triggered in these patients by the immunosuppressive effects of dasatinib, subsequently leading to the preferential expansion of individual CD8 þ T-cell or NK-cell clones with properties that rendered them more resistant to dasatinib-mediated inhibition in the context of enhanced viral antigenic load. Our dasatinib sensitivity studies support this hypothesis (Figure 2 and Supplementary Figure S1 ). Furthermore, monoclonal or oligoclonal LGL expansions have been described in states of reduced immunity, for example after allogeneic stem cell transplantation, 32 and during chronic viral infections. 33, 34 After allogeneic stem cell transplantation, LGL expansions typically occur within 3-15 months and are primarily observed in the context of chronic viral infections. This indicates that chronic antigen-driven T-cell stimulation may contribute to, or even cause, LGL expansions. Of note, LGL expansions have been associated with long-term remission in leukemic states. 32 Indeed, this favorable outcome also applies to dasatinib-treated patients with monoclonal or oligoclonal LGL expansions (Table 1) . [15] [16] [17] It is tempting to speculate that crossreactive CD8
þ T-cells 35, 36 driven by viral recrudescence and fortuitously targeting leukemia-associated antigens, might mediate these beneficial effects. In this light, it is notable that the majority of LGL patients (11/16) in this study were HLA-A*02 þ , which might restrict both virus-specific and leukemia-associated antigen-specific epitopes in this setting. Previous descriptions of improved survival associated with HLA-A*02 þ and CMV IgG seropositivity in the allogeneic transplantation setting are consistent with this notion. 37 All LGL patients exhibited distinct CD8 þ T-cell populations comprising both CD8 high and CD8 low T-cells. This was true for both the total and NLVPMVATV-specific CD8 þ T-cell populations. The CD8 high T-cell subset was uniformly the most functionally responsive on restimulation. A similar phenotypic dichotomy (CD8 high vs CD8 low ) has been described previously for HIV-specific CD8 þ T-cells, both during the initiation and discontinuation of antiretroviral therapy. 38 Thus, dynamic perturbations of viral load can elicit such phenotypic patterns within the cognate CD8 þ T-cell population. Consistent with this explanation, both the CD8 high and CD8 low NLVPMVATVspecific CD8
þ T-cell populations were phenotypically and clonotypically similar within individuals, thereby indicating that Table 3 Phenotypic features of NK-cells (either gated on CD16 + or CD56 + first) in patients with T, NK or T+NK LGL expansion the same antigen-specific clonotypes can exist in different states of activation during dasatinib-associated LGL expansion. Of further note in this regard, it has been shown previously that CMV-specific CD8 þ T-cells can dominate the memory pool in IgG seropositive individuals. 39, 40 Thus, CMV reactivation could potentially explain the dichotomous pattern of CD8 expression within the total CD8 þ T-cell population, as the NLVPMVATVspecific response likely only measures a small fraction of the overall CD8 þ T-cell response to CMV. In addition, high CD8 expression may reflect the inhibition of co-receptor downregulation by dasatinib.
7,26 CD8 low T-cells have been observed primarily in chronic infections with persistent antigenic stimula- 
þ T-cells that expressed CD57, PD-1 and CD57, or PD-1 without CD57. (g) CD69 and CD127 expression profiles of NLVPMVATV-specific
þ T-cells that expressed CD57, PD-1 and CD57, or PD-1 without CD57. PBMCs or BMMCs were stained sequentially with a live/dead fixable dye, CMV pp65 495À503 /HLA-A*0201-APC tetramer, and one of two different polychromatic surface marker-specific monoclonal antibody panels; for one of the surface marker-specific monoclonal antibody panels, cells were then also stained with streptavidin-Pacific Blue. Data were acquired using a 20-parameter FACSAria II flow cytometer and analyzed with FlowJo software. The time points were: 1 ¼ 46 days, 2 ¼ 107 days, 3 ¼ 117 days, 4 ¼ 138 days, 5 ¼ 358 days, 6 ¼ 446 days, 7 ¼ 463 days, 8 ¼ 488 days, 9 ¼ 491 days; 11 ¼ BM sample from 358 days after the start of dasatinib therapy. The CMV load (copies/ml) is shown in all panels. All analyses were conducted with cryopreserved samples from patient 6 (Table 1) . tion, such as HIV infection, 41, 42 and may represent long-lived anergic cells in some cases. 43 In LGL patients, we found an increased frequency of apoptotic T-cells compared with non-LGL patients and healthy controls. This finding may reflect strong in vivo proliferation of the LGL cells, potentially driven by viral antigens, leading to exhaustion and increased susceptibility to apoptosis. The observed relative impairment of NK-cell cytotoxic activity against K562 cells in NK LGL patients could be due to a similar process. In line with these findings, both CD8 þ T-cells and NK-cells expressed high levels of CD57 in patients with LGL expansions of the corresponding cell subsets. CD57 expression is a marker of replicative senescence and indicative of altered functional capacities. 44 However, this reduced cytotoxic activity was restorable after pretreatment of NK-cells with IL-2, which argues for a transient effect with sustained functionality as typified by recently primed or anergic cells.
The increased IP-10, IL-6, MIG and IL-2R levels observed in LGL patients could conceivably contribute to improved therapeutic responses because these cytokines/chemokines direct the chemotaxis of monocytes, T-cells, NK-cells and dendritic cells. Such chemotactic effects have been shown to be relevant for leukemia control. 45, 46 Of note, some of these soluble factors are typically produced by antigen-specific CD8
þ T-cells during viral infections and are associated with anti-viral processes. Indeed, a causative role for infections with herpes viruses has already been postulated in the pathogenesis of LGL expansions. 47 The elevated cytokine/chemokine levels in LGL patients could therefore indicate a higher degree of viral antigen-driven cellular immune activation enhanced by an intrinsic dysregulation of homeostasis. Consistent with these ideas, we observed the highest levels of IP-10, IL-6, MIG and IL-2R in the plasma of LGL patients with symptomatic CMV reactivation. Notably, we also detected CD8 þ T-cells specific for the leukemia-associated antigen PR1 in 3 LGL patients, 2 of them with complete remission status despite initially poor prognoses. Such CD8 þ T-cell populations are difficult to detect in peripheral blood; 48 it is therefore possible that larger numbers of these cells might reside in the bone marrow of patients with dasatinib-associated LGL, contributing to the link between elevated levels of cytokines/chemokines and favorable outcome.
In summary, we show here that the expanded lymphocyte populations in dasatinib-associated LGL patients are primarily CD27 À and CD57 þ , a phenotype associated with late differentiated effector memory cells. This finding is in general agreement with previous descriptions of anergic clonal T-cell expansions in other malignant diseases such as multiple myeloma, 49 myelodysplastic syndrome 50 and Waldenstrom's macroglobulinaemia. 51 In addition, we provide strong evidence that the LGL expansions, which are linked to a favorable outcome during dasatinib therapy, are associated with CMV reactivation. A causative role of CMV in this process has yet to be proven, but the possibility that a recrudescent virus can elicit cellular immune responses capable of controlling leukemia is worthy of further study.
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